Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

Merck & Co (NYSE:MRK)., the second-largest U.S. drugmaker by revenue, is facing a jury trial over accusations that it ...

In a report released on January 24, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other stocks Jim Cramer recently discussed. In his latest appearance on CNBC’s Squawk on the ...

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

Robert F. Kennedy Jr. would retain legal fees earned from litigation against drugmaker Merck if he is confirmed as President ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Visitors can capture their photos with the Red Card at the stand to contribute to a powerful visual Mosaic symbol of ...

2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive ...